Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

Phase 3

Recruiting

Conditions: Relapsed or Refractory Acute Myeloid Leukemia

Interventions: Drug: Dexamethasone
Drug: Amsacrine
Drug: Cytarabine
Drug: Azacitidine

First Posted Date: 2018-12-05

Last Posted Date: 2023-09-21

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 142

Registration Number: NCT03765541

Locations: 🇫🇷
Institut Paoli Calmettes, Marseille, France
🇫🇷
CHU de Limoges, Limoges, France
🇫🇷
CHU de Bordeaux, Pessac, France

and more 7 locations

HDM201 Added to CT in R/R or Newly Diagnosed AML

Phase 1

Withdrawn

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: HDM201
Drug: cytarabine
Drug: anthracycline
Drug: liposomal cytarabine/daunorubicin
Drug: posaconazole
Drug: midazolam
Drug: midostaurin

First Posted Date: 2018-11-30

Last Posted Date: 2020-01-09

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03760445

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Phase 2

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Carboplatin
Drug: Ifosfamide
Drug: Etoposide
Biological: Rituximab
Drug: Carmustine
Drug: Cytarabine
Drug: Melphalan
Other: Autologous HSCT
Drug: Acalabrutinib

First Posted Date: 2018-11-09

Last Posted Date: 2022-07-22

Lead Sponsor: Swedish Medical Center

Target Recruit Count: 47

Registration Number: NCT03736616

Locations: 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Prexasertib
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2018-11-08

Last Posted Date: 2019-06-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03735446

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Daunorubicin
Drug: Daunorubicin Hydrochloride
Drug: Pinometostat

First Posted Date: 2018-10-30

Last Posted Date: 2024-06-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6

Registration Number: NCT03724084

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma

Phase 2

Withdrawn

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Methotrexate
Drug: Cytarabine

First Posted Date: 2018-10-25

Last Posted Date: 2020-04-13

Lead Sponsor: Brown University

Registration Number: NCT03719560

Locations: 🇺🇸
Roxanne Wood, Providence, Rhode Island, United States

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Ibrutinib
Drug: Methotrexate
Biological: Rituximab
Drug: Venetoclax
Drug: Vincristine Sulfate

First Posted Date: 2018-10-18

Last Posted Date: 2024-11-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT03710772

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Venetoclax
Drug: Daunorubicin
Drug: Cytarabine

First Posted Date: 2018-10-17

Last Posted Date: 2024-08-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 64

Registration Number: NCT03709758

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cytarabine
Drug: Daunorubicin
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Drug: Uproleselan

First Posted Date: 2018-10-10

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 670

Registration Number: NCT03701308

Locations: 🇺🇸
Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Community Cancer Institute, Clovis, California, United States

and more 185 locations

Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Selinexor
Drug: fludarabine
Drug: idarubicin
Drug: cytarabine
Drug: G-CSF

First Posted Date: 2018-09-07

Last Posted Date: 2020-05-20

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 16

Registration Number: NCT03661515

Locations: 🇪🇸
Hospital San Pedro de Alcántara,, Cáceres, Spain
🇪🇸
Hospital la Fe, Valencia, Spain
🇪🇸
Hospital Germans Tries i Pujol, Badalona, Badalona, Spain

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy